TED

Thrive Health IV Centers Expand in Key Markets and Open Research Clinics

Retrieved on: 
Tuesday, September 5, 2023
Exophthalmos, Partnership, Graves' ophthalmopathy, Clinical trial, Woman, Research, Approximation error, Doctor of Philosophy, Science, Grave, Patient, University of California, San Francisco Fetal Treatment Center, FACS, Thyroid disease, FDA, Health, Hyperthyroidism, Autoimmunity, TED, Medical device, Pharmaceutical industry, MD

BEVERLY HILLS, Calif., Sept. 5, 2023 /PRNewswire-PRWeb/ -- Thrive Health IV, founded by renowned board certified oculoplastic surgeon, Raymond Douglas, MD, PhD, announced today the opening of three new dedicated treatment centers of excellence in Miami, Florida, Des Moines, Iowa and Chicago, Illinois for Thyroid Eye Disease [TED] and other rare ophthalmic conditions.

Key Points: 
  • Thrive Health IV leverages cutting edge science and exceptional concierge care in the growing category of medical biologics and new disease modalities.
  • Thrive Health IV is also launching a new research division and operating clinical trials at all sites, propelling Thrive Health IV to the forefront of all potential therapies for auto-immune thyroid related eye disease and other rare ophthalmic conditions.
  • Additional Thrive Health IV locations with research and clinical trial operations are set to open in two new states in three additional markets as a next phase before 2024.
  • Thrive Health IV centers of excellence, also offers ongoing patient care management that includes monitoring blood sugar and complimentary audiology testing.

Biopharmaceutical Giant Amgen to Settle FTC and State Challenges to its Horizon Therapeutics Acquisition

Retrieved on: 
Saturday, September 2, 2023
Regulations.gov, Amgen, Register, Contract, Commission, CRG, Federal, Pharmacy, Blog, Social media, Federal Trade Commission, Sale, Competition, Graves' ophthalmopathy, District court, Acquisition, Federal Register, Patient, FTC, Compliance, FDA, Douglas v. U.S. District Court ex rel Talk America, News, TED, Generic drug, Health insurance, Fine chemical, Dietary supplement, Cryptocurrency, Pegloticase
Key Points: 

Biopharmaceutical Giant Amgen to Settle FTC and State Challenges to its Horizon Therapeutics Acquisition

Retrieved on: 
Saturday, September 2, 2023
Regulations.gov, Amgen, Register, Contract, Commission, CRG, Federal, Pharmacy, Blog, Social media, Federal Trade Commission, Sale, Competition, Graves' ophthalmopathy, District court, Acquisition, Federal Register, Patient, FTC, Compliance, FDA, Douglas v. U.S. District Court ex rel Talk America, News, TED, Generic drug, Health insurance, Fine chemical, Dietary supplement, Cryptocurrency, Pegloticase

The Federal Trade Commission reached a proposed consent order with Amgen Inc. to address the potential competitive harm that would result from Amgen’s $27.8 billion acquisition of Horizon Therapeutics plc.

Key Points: 
  • The Federal Trade Commission reached a proposed consent order with Amgen Inc. to address the potential competitive harm that would result from Amgen’s $27.8 billion acquisition of Horizon Therapeutics plc.
  • In addition, Amgen may not condition any product rebate or contract terms related to an Amgen product on the sale or positioning either one of these drugs.
  • Under the terms of the consent order, Amgen is required seek FTC such prior approval through 2032 and notify the states if it is seeking Commission approval.
  • The FTC’s proposed consent order, among other conditions, also requires that Amgen:



  • In May 2023, the FTC filed a complaint in the U.S. District Court for the Northern District of Illinois to block the proposed transaction.
  • This was the FTC’s first litigated challenge to a pharmaceutical merger in more than a decade.
  • Further details about the proposed order can be found in the analysis to aid public comment.
  • The FTC will publish the consent agreement package in the Federal Register shortly.

Focus on 'Tipping Point Skills' Makes LifeLabs Learning 55th Fastest-Growing Education Company in America on the 2023 Inc. 5000

Retrieved on: 
Tuesday, August 29, 2023
Growth, The New York Times, TED, Tutoring, Nursing

NEW YORK, Aug. 29, 2023 /PRNewswire/ -- LifeLabs Learning, the source for instantly useful manager and team upskilling programs, is thrilled to announce its debut on the Inc. 5000 list, an annual compilation of the fastest-growing companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy's most dynamic segment — its independent, entrepreneurial businesses. With a three-year revenue growth of 193%, LifeLabs Learning secured its place in the top 3,000, ranking at number 2,769.

Key Points: 
  • NEW YORK, Aug. 29, 2023 /PRNewswire/ -- LifeLabs Learning, the source for instantly useful manager and team upskilling programs, is thrilled to announce its debut on the Inc. 5000 list, an annual compilation of the fastest-growing companies in America.
  • With a three-year revenue growth of 193%, LifeLabs Learning secured its place in the top 3,000, ranking at number 2,769.
  • LifeLabs Learning ranked on the Inc. 5000 list as America's 55th fastest-growing education company.
  • For complete results of the Inc. 5000, including company profiles and an interactive database, go to https://www.inc.com/profile/lifelabs-learning .

Tourmaline Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TOUR006, an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED)

Retrieved on: 
Monday, August 28, 2023
Arm, Eye, Food and Drug Administration, Graves' ophthalmopathy, IL-6, Inflammation, Biomarker, MD, Patient, Autoimmune disease, ASCVD, Moyamoya disease, FDA, Therapy, Food, TED, Pharmaceutical industry, Tourmaline

TOUR006 is a fully-human, anti-IL-6 antibody with differentiated properties including high binding affinity to IL-6 and a naturally long half-life.

Key Points: 
  • TOUR006 is a fully-human, anti-IL-6 antibody with differentiated properties including high binding affinity to IL-6 and a naturally long half-life.
  • TED, also known as Graves’ ophthalmopathy, is an autoimmune disease characterized by inflammation and disfigurement around the eye, which can be sight-threatening in severe cases.
  • The approximately 81 participants planned to be enrolled (27 in each arm) will be moderate to severe TED patients who are in the active phase of disease.
  • The primary endpoint for this trial will be proptosis response, or reduction of abnormal eye protrusion, measured at week 20.

Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups

Retrieved on: 
Wednesday, August 23, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Managed Care, Health, Other Health, Rarey technique, Partnership, Education, NMO, Overalls, NMOSD, Organization, Rare, Patient, Scholarship, Neuromyelitis optica spectrum disorder, Disease, TED, Pharmaceutical industry, Nursing

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked first in overall corporate reputation among rare disease patient groups around the world who were familiar with the company.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked first in overall corporate reputation among rare disease patient groups around the world who were familiar with the company.
  • “We are honored by the feedback that rare disease patient advocacy groups provided within the PatientView report,” said Matt Flesch, vice president, patient advocacy and product communications, Horizon.
  • From the programs that we support to the initiatives that we create; our belief is that meaningful and appropriate collaboration with patient advocacy groups is core to all our work at Horizon.”
    In the PatientView report summarizing survey results from rare disease groups, 91 rare disease patient advocacy groups said they were familiar with Horizon and 59 said they worked with the company.
  • In previous PatientView results released in the first half of 2023 , Horizon ranked second in overall corporate reputation and first in patient centricity and integrity among all patient advocacy groups around the world who worked with the company (not just rare disease groups), and first in overall corporate reputation among patient advocacy groups in the United States.

ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, August 14, 2023
IPO, Axial spondyloarthritis, IV, Spermatogenesis, Nektar Therapeutics, Doctor of Philosophy, Pain, Graves' ophthalmopathy, Psoriatic arthritis, Dermatology, Teprotumumab, MD, Patient, Randomized controlled trial, Prurigo nodularis, DMC, Disease, Tissue, SLRN, Disability, Human, IL-17A, Data, Hearing, Uveitis, Rheumatology, Growth, FDA, Safety, D, Secukinumab, Neutropenia, Exercise, POC, Eosinophilic esophagitis, Allergy, B cell, AAD, Webcast, CFO, Enthesitis, LOS, Research, Hives, Therapy, Inflammation, Huber loss, CU, Data monitoring committee, TED, Pharmaceutical industry, Vaccine, Management, Rare-earth element, HS, Part, Hidradenitis suppurativa

LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.   

Key Points: 
  • LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.
  • Enrollment of the double-blind, placebo-controlled Part B of the Phase 2b/3 trial evaluating izokibep in HS completed ahead of schedule, accelerating anticipated top-line results into the third quarter 2023.
  • Net Loss: Net loss totaled $26.0 million for the second quarter of 2023, compared to $14.5 million for the second quarter of 2022.
  • ET to review its second quarter 2023 financial results.

Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update

Retrieved on: 
Monday, August 14, 2023
Sarcoidosis, Lupus, CIDP, SG, DM, IQVIA, Calendar, Myasthenia gravis, NIU, Prescription, Atopic dermatitis, Research, GD, SLE, Pharmacy, Ulcerative colitis, Psoriasis, MDS, Acquisition, Patient, Transfusion-dependent anemia, Drug discovery, R, FDA, Safety, TED, Pharmaceutical industry, Life insurance, Cryptocurrency, Dermatomyositis, Roivant Sciences

Dermavant: For the first quarter ended June 30, 2023, Roivant reported VTAMA net product revenue of $16.7M, representing a 26% gross-to-net yield for the quarter.

Key Points: 
  • Dermavant: For the first quarter ended June 30, 2023, Roivant reported VTAMA net product revenue of $16.7M, representing a 26% gross-to-net yield for the quarter.
  • First Quarter Ended June 30, 2023, Financial Summary
    As of June 30, 2023, the company had consolidated cash, cash equivalents and restricted cash of $1.4 billion.
  • Net loss was $327.8 million for the three months ended June 30, 2023, compared to $353.8 million for the three months ended June 30, 2022.
  • Non-GAAP net loss was $211.5 million for the three months ended June 30, 2023, compared to $210.7 million for the three months ended June 30, 2022.

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

Retrieved on: 
Thursday, August 10, 2023
Common stock, IPR, CIDP, D, Information technology, Calendar, Research, GD, Neonatal Fc receptor, Safety, Pharmaceutical industry, Cryptocurrency, TED

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal first quarter ended June 30, 2023.

Key Points: 
  • NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal first quarter ended June 30, 2023.
  • Immunovant is studying batoclimab, the company’s lead subcutaneously administered FcRn inhibitor, in four autoimmune indications – MG, TED, CIDP and GD.
  • Top-line data from the Phase 3 clinical trial in MG are expected in the second half of calendar year 2024.
  • R&D Expenses: Research and development expenses were $50.6 million for the three months ended June 30, 2023, compared to $28.4 million for the three months ended June 30, 2022.

AltaSea’s Annual Blue Hour to Honor Women Stewards of the Ocean

Retrieved on: 
Wednesday, August 9, 2023
Sustainability, Events, Concerts, Philanthropy, Women, Environment, Environmental Issues, Environmental Health, Maritime, Fund Raising, Transport, Science, Arts, Museums, Entertainment, Consumer, Other Science, Workforce, AAF, Woods Hole Oceanographic Institution, Chicago Innovation Awards, Emeritus, Harbor, Culture, Santa Monica College, Aquaculture, Port, Foot, Woman, Denver 2008 Convention Host Committee, Southern California Gas Company, The Stand, Student, Berth, 900 Rosalinde, Climate change, City, Nature, Museum, Academy Awards, City National Bank, Air Products, Blue Hour, Robotics, Beneficial State Bank, TED, Interior design, Tourism, Whale

Blue Hour: Above and Below will celebrate both local and global trailblazers who are paving the path for innovation in the blue economy, as well as feature over 20 local artists.

Key Points: 
  • Blue Hour: Above and Below will celebrate both local and global trailblazers who are paving the path for innovation in the blue economy, as well as feature over 20 local artists.
  • The Host Committee for AltaSea’s fourth annual Blue Hour includes former California Governor Arnold Schwarzenegger; renowned ocean explorers Sylvia Earle, Dr. Bob Ballard, and Ashlan and Phillippe Cousteau; and nonprofit leader Barbara Stanton.
  • A full list of artists – along with some previews of the art – can be found on the Blue Hour website .
  • Her leadership and vision were instrumental in establishing Project Blue, fostering community connections, and advancing the organization's mission.